Trial Profile
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs and monotherapy who have an Inadequate Response to Current Non-Biologic or Biologic DMARDs.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms ACT-STAR
- Sponsors Roche
- 26 Aug 2020 Results of a pooled analysis from twelve phase 3 and 4 clinical trials: ACT-RAY, ACT-STAR, ACT-SURE, ADACTA, AMBITION, BREVACTA, COMP-ACT, LITHE, OPTION, ROSE, SUMMACTA and TOWARD assessing predictors of response, including demographics, disease characteristics at baseline published in the Rheumatology
- 29 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 16 Apr 2012 Actual patient number changed from 889 to 886 according to ClinicalTrials.gov record.